← Eichor
Study identifier: NCT05889585 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant

Condition: Germ Cell Tumor  ·  Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

PhaseNA
Planned participants180
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Intensified chemotherapy is an effective treatment in 30-70% of patients with refractory germ cell tumor. Since most cases are diagnosed before the age of 40, survivors can expect to live another 30 to 50 years after being successfully treated. Long-term side effects and physical and emotional consequences can therefore have a significant impact on daily life. To date, no data of this type is available in France. This study will help clinicians better understand the long-term consequences for relapsed patients receiving high-dose chemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Natacha NAOUN, MD  ·  + 33 (0)1 42 11 42 11  ·  natacha.naoun@gustaveroussy.fr

Karim Fizazi, MD, Prof.  ·  + 33 (0)1 42 11 43 17  ·  karim.fizazi@gustaveroussy.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Gustave RoussyVillejuif, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05889585